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Search strategies in PubMed (September 10, 2016) 
adiponectin [MeSH] OR adiponectin OR ADIPOQ OR ADPN) AND (diabetes mellitus [MeSH] OR 
diabetes OR diabetic OR diabetics) 
Restricted to “human study”, and the time period was between April 10, 2009 to September 10, 2016. 
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Supplemental Table S1. Pearson correlation coefficients between adiponectin and age, body mass index, levels of lipids, high-sensitivity C-
reactive protein, random glucose and insulin in control participants, the Singapore Chinese Health Study 
Marker Adiponectin Age BMI TC HDL-C TG 
Ratio of TG to 
HDL-C 
Hs-CRP 
Random 
glucose 
Random 
insulin 
Adiponectin 1.00          
Age 0.11a 1.00         
BMI -0.15a -0.01 1.00        
TC 0.04 -0.02 -0.02 1.00       
HDL-C 0.49a -0.09a -0.18a 0.29a 1.00      
TG  -0.43a 0.05 0.16a 0.13a -0.54a 1.00     
Ratio of TG to HDL-C -0.50a 0.07 0.19a -0.01 -0.78a 0.95a 1.00    
Hs-CRP -0.19a 0.06 0.26a 0.05a -0.14a 0.11a  0.14
a 1.00   
Random glucose -0.01 0.08 0.03 -0.07 -0.06 0.06 0.07 0.04 1.00  
Random insulin -0.20a 0.04 0.23a -0.03 -0.29a 0.35a  0.36
a 0.15a 0.66a 1.00 
Abbreviations: BMI, body mass index; TC, total cholesterol; HDL-C, HDL cholesterol; TG, triglycerides; hs-CRP, high-sensitivity C-
reactive protein. 
aCorrelation coefficients are statistically significant at P <0.05.  
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Supplemental Table S2. Odds ratio (95% confidence interval) for risk of type 2 diabetes according to 
tertiles of adiponectin, stratified by body mass index, physical activity, smoking, and high-sensitivity C-
reactive protein levels, using unconditional logistic regression model, the Singapore Chinese Health 
Studya 
Variables 
Tertiles of adiponectin concentration 
P for trendb P for interactionc 
T1 T2 T3 
Gender      
    Male 1.00 0.71 (0.38-1.31) 0.48 (0.18-1.25) 0.097 
0.26 
    Female 1.00 0.67 (0.33-1.35) 0.21 (0.08-0.51) 0.001 
Body mass index      
    <23.0 kg/m2 1.00 1.09 (0.62-1.93) 0.59 (0.29-1.21) 0.21 
0.041 
    ≥23.0 kg/m2 1.00 0.76 (0.47-1.22) 0.36 (0.19-0.69) 0.003 
Physical activity      
    <0.5 hour/week 1.00 0.96 (0.64-1.43) 0.54 (0.23-0.54) 0.042 
0.10 
    ≥0.5 hour/week 1.00 0.61 (0.28-1.36) 0.21 (0.07-0.68) 0.01           
Smoking      
    Never 1.00 0.84 (0.55-1.29) 0.49 (0.29-0.83) 0.011 
0.27 
    Ever 1.00 0.93 (0.46-1.86) 0.28 (0.09-0.85) 0.07 
High-sensitivity C-reactive protein levelsd     
    ≤1.2 mg/L 1.00 0.85 (0.48-1.53) 0.58 (0.29-1.15) 0.13 
0.64 
    >1.2 mg/L 1.00 0.87 (0.55-1.39) 0.34 (0.18-0.65) 0.004 
aModel was adjusted for age at blood taken (continuous), gender (male, female), dialect group 
(Cantonese, Hokkien), smoking (never, ever smoker), alcohol intake (never, ever drinker), weekly activity 
(<0.5, ≥0.5 hours/week), education level (primary school and below, secondary or above), history of 
hypertension (yes, no), fasting status (yes, no), body mass index (continuous), high-sensitivity C-reactive 
protein (mmol/L), the ratio of triglycerides to HDL cholesterol, random glucose (mmol/L) and random 
insulin (mIU/L) (all in tertiles) except for the respective stratification variable. 
bLinear trend was tested by using the median level of each tertile of adiponectin level.  
cInteraction was tested between stratified variable (dichotomized) and adiponectin (per log increment) in 
the models. 
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dMedian cutoff for high-sensitivity C-reactive protein was calculated among controls and defined as 1.2 
mg/L.  
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Supplemental Table S3. Summary statistics to assess adiponectin in predicting type 2 diabetes, the 
Singapore Chinese Health Study 
Variable 
Multivariable model 
Discrimination 
(AUC [95% CI]) 
Calibration 
(AIC) 
NRI IDI 
Base model 1a 0.74 (0.71-0.77) 595   
Base model 1a + adiponectin  0.76 (0.73-0.79)d 566 33% 0.03 
Base model 2b  0.82 (0.80-0.85) 389   
Base model 2b + adiponectin 0.83 (0.80-0.85) 376 19% 0.01 
Base model 3c 0.87 (0.84-0.89) 329   
Base model 3c + adiponectin 0.87 (0.85-0.89) 325 12% 0.01 
Abbreviations: AUC, area under the receiver operating characteristic curve; CI, confidence interval; AIC, 
Akaike information criterion; NRI, net reclassification improvement; IDI, integrated discrimination 
improvement. 
aBase model 1 included education level (no, primary school, secondary and above), weekly moderate-to-
vigorous activity (<0.5, 0.5-3.9 hours/week, ≥4 hours/week), history of hypertension (yes, no), body mass 
index (continuous), and tertiles of triglycerides, HDL cholesterol and high-sensitivity C-reactive protein. 
bBase model 2 included variables in base model 1 plus tertiles of random glucose and random insulin. 
cBase model 3 included variables in base model 1 plus tertiles of HbA1c and random insulin. 
dCompared with the base model, the increment in AUC value was statistically significant (P <0.05). 
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Supplemental Table S4. Reclassification of type 2 diabetes cases and controls with no risk categories based on their plasma concentrations of 
adiponectin, the Singapore Chinese Health Study  
Base model 1a + adiponectin All 
Assigned to higher 
diabetes risk 
Assigned to lower 
diabetes risk 
NRI 
Expected number of event participants 571 352 219  Among event participants 23.3% 
Expected number of non-event 
participants 
571 257 314  Among non-event 
participants 
10.0% 
 Overall original (95% CI) 33.3% (21.7%, 44.9%) 
Base model 2b + adiponectin All 
Assigned to higher 
diabetes risk 
Assigned to lower 
diabetes risk 
NRI 
Expected number of event participants 571 334 237  Among event participants 17.1% 
Expected number of non-event 
participants 
571 280 291  Among non-event 
participants 
2.0% 
 Overall original (95% CI) 19.1% (6.8%, 31.4%) 
Base model 3c + adiponectin All 
Assigned to higher 
diabetes risk 
Assigned to lower 
diabetes risk 
NRI 
Expected number of event participants 571 319 252  Among event participants 18.7% 
Expected number of non-event 
participants 
571 284 287  Among non-event 
participants 
11.1% 
 Overall original (95% CI) 12.3% (0%, 24.6%) 
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Abbreviations: NRI: net reclassification improvement. 
aBase model 1 included education level (no, primary school, secondary and above), weekly moderate-to-vigorous activity (<0.5, 0.5-3.9 
hours/week, ≥4 hours/week), history of hypertension (yes, no), body mass index (continuous), and tertiles of triglycerides, HDL cholesterol 
and high-sensitivity C-reactive protein. 
bBase model 2 included variables in base model 1 plus tertiles of random glucose and random insulin.  
cBase model 3 included variables in base model 1 plus tertiles of HbA1c and random insulin. 
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Supplemental Table S5. Stratified analyses of adiponectin concentrations and risk of type 2 diabetes 
 Risk of type 2 diabetes 
RR (95% CI) n of prospective studies I2 (%) P for Heterogeneity 
Overall results 0.54 (0.47-0.61) 34 48.8 0.001 
Trim and fill method 0.63 (0.50-0.76) 34 64.0 0.001 
Sex     
Men 0.67 (0.50-0.90) 4 0 0.60 
Women 0.32 (0.20-0.52) 2 0 0.47 
Mixed 0.53 (0.45-0.62) 28 53.6 0.001 
Study Location     
US 0.62 (0.49-0.79) 9 40.5 0.10 
Europe or Oceania 0.50 (0.43-0.58) 18 29.6 0.12 
Asia 0.48 (0.32-0.73) 7 69.4 0.003 
Ethnicity     
Caucasian Whites 0.49 (0.43-0.57) 19 25.6 0.15 
East Asians 0.51 (0.36-0.73) 8 64.3 0.01 
Others, mixed 0.64 (0.48-0.85) 7 51.0 0.06 
Mean age groups     
<60 years 0.53 (0.45-0.61) 24 49.8 0.003 
≥60 years 0.56 (0.41-0.75) 10 47.1 0.049 
Follow-up years     
<3 years 0.33 (0.06-0.75) 2 82.7 0.02 
≥3 years 0.53 (0.47-0.61) 32 46.7 0.002 
Sample size     
<2000 0.50 (0.42-0.59) 22 41.3 0.02 
≥2000 0.53 (0.47-0.61) 12 60.2 0.004 
Publication year     
<2010 0.57 (0.45-0.71) 14 43.6 0.04 
≥2010 0.52 (0.44-0.61) 20 51.5 0.001 
Laboratory assays for adiponectin     
     ELISA 0.53 (0.45-0.63) 20 56.2 0.001 
     RIA 0.47 (0.29-0.75) 5 60.2 0.04 
     Others 0.60 (0.47-0.75) 9 13.6 0.32 
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Study qualityb     
High (8-9) 0.56 (0.48-0.66) 24 44.1 0.01 
Low (≤7) 0.47 (0.35-0.62) 10 62.2 0.01 
Level of adjustmentc 
Level 1 0.40 (0.34-0.47) 23 69.1 <0.001 
Level 2 0.39 (0.30-0.50) 9 55.3 0.02 
Level 3  0.53 (0.48-0.60) 28 22.9 0.14 
Level 4 0.63 (0.49-0.80) 9 45.6 0.07 
Abbreviations: RR, relative risk. 
aThe results are presented using the random-effects model. 
bThe study quality scored from 0 to 9, with higher score indicating higher quality. 
cLevel of adjustment was defined as below: level 1 was basic models without adjustment for metabolic 
biomarkers; level 2 was models adjusted for lipids and/or inflammatory markers; level 3 was models 
adjusted for either insulin sensitivity markers or glycaemia markers; level 4 was models adjusted for both 
insulin sensitivity markers and glycaemia markers. 
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Supplemental Table S6. The extracted data for the dose-response meta-analysis from 12 available 
studies  
First author 
(reference) 
Adiponectin 
category 
Adiponectin 
median, µg/ml 
Number of 
participants 
Number of 
cases 
RR (95% CI) 
Keonig1  Tertile 1 3.81 298 57 1 
 Tertile 2 6.32 294 31 0.63 (0.40-0.99) 
 Tertile 3 10.6 295 27 0.81 (0.50-1.33) 
Snijder2 (male) Quartile 1 8.3 145 18 1 
 Quartile 2 9.8 151 16 0.79 (0.38-1.67) 
 Quartile 3 10.6 143 14 0.71 (0.33-1.55) 
 Quartile 4 12.4 145 12 0.61 (0.27-1.40) 
Snijder2 (female) Quartile 1 3.5 170 27 1 
 Quartile 2 7.2 170 14 0.58 (0.28-1.20) 
 Quartile 3 8.2 170 11 0.47 (0.22-1.01) 
 Quartile 4 15.8 170 6 0.27 (0.10-0.73) 
Wannamathee3 Tertile 1 2.7 1189 55 1 
 Tertile 2 5.4 1189 32 0.66 (0.42-1.04) 
 Tertile 3 9.7 1189 18 0.40 (0.23-0.70) 
Heidermann4 Quintile 1 8.1 775 548 1 
 Quintile 2 13.9 449 221 0.46 (0.35-0.60) 
 Quintile 3 17.9 366 139 0.31 (0.23-0.42) 
 Quintile 4 21.7 300 73 0.21 (0.15-0.30) 
 Quintile 5 28.4 284 57 0.17 (0.12-0.25) 
Thorand5 Tertile 1 8.3 709 236 1 
 Tertile 2 11.5 646 148 0.53 (0.37-0.76) 
 Tertile 3 15.7 579 76 0.38 (0.27-0.53) 
Kizer6a  Quartile 1 7.2 950 146 1 
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 Quartile 2 10.8 950 73 0.74 (0.55-1.01) 
 Quartile 3 15.0 951 49 0.66 (0.46-0.96) 
 Quartile 4 23.6 951 41 0.79 (0.50-1.23) 
Li7 Quintile 1 4.3 964 86 1 
 Quintile 2 6.3 697 33 0.58 (0.39-0.87) 
 Quintile 3 7.9 487 15 0.41 (0.24-0.72) 
 Quintile 4 10 431 10 0.34 (0.18-0.68) 
 Quintile 5 13.9 429 20 0.72 (0.42-1.25) 
Lilja8 (male) Quartile 1 3.1 388 195 1 
 Quartile 2 7.5 294 101 0.83 (0.62-1.12) 
 Quartile 3 10.5 224 31 0.40 (0.25-0.64) 
 Quartile 4 15.2 235 43 0.52 (0.34-0.81) 
Lilja8 (female) Quartile 1 4.6 346 149 1 
 Quartile 2 11.6 274 76 0.70 (0.50-0.98) 
 Quartile 3 16.2 218 21 0.38 (0.22-0.64) 
 Quartile 4 23 218 21 0.44 (0.25-0.76) 
Yamamoto9 Quartile 1 2.6 1145 76 1 
 Quartile 2 6 1138 60 0.79 (0.55-1.12) 
 Quartile 3 8.2 1174 47 0.60 (0.41-0.88) 
 Quartile 4 11.8 1134 31 0.40 (0.25-0.64) 
Marques-Vidal10 Quartile 1 3.7 913 71 1 
 Quartile 2 7.3 969 58 0.97 (0.64-1.47) 
 Quartile 3 11.3 969 48 0.84 (0.55-1.30) 
 Quartile 4 17.3 991 31 0.64 (0.40-1.03) 
Neville11a Tertile 1 1.9 467 73 1 
 Tertile 2 5.2 467 51 0.92 (0.60-1.43) 
Page 14 of 18 
 
 Tertile 3 8.6 463 27 0.54 (0.29-0.99) 
Current study Quartile 1 5.3 420 275 1 
 Quartile 2 7.5 305 161 0.65 (0.37-1.15) 
 Quartile 3 9.4 234 91 0.62 (0.34-1.14) 
 Quartile 4 12.8 183 44 0.33 (0.15-0.73) 
Abbreviations: RR, relative risk. 
aNumbers of cases were estimated from the incidence rates for type 2 diabetes reported in the studies. 
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Supplemental Figure S1. Flowchart of the Singapore Chinese Health Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recruited 63,257 
participants 
Re-interviewed 52,325; 
32,575 donated blood 
Re-interviewed 39,528; 
25,477 donated blood at 
follow-up 1 
Baseline (1993-1998) Follow-up 1 (1999-2004) Follow-up 2 (2006-2010) 
Case-control selection 
 
Sample size: 571 cases and 571 controls 
 
Cases:         1) donated blood; 
                    2) reported no diabetes at blood donation; 
                    3) reported to be diagnosed of diabetes at follow-up 2. 
 
Controls:     1) donated blood; 
                    2) reported no diabetes at follow-up 1 and follow-up 2;  
                    3) HbA1c <6.0%. 
 
Matching factors: age, gender, dialect group and date of blood collection 
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Supplemental Figure S2. Flowchart of the meta-analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure legend 
aThe last meta-analysis referred to Li et al.  
Li, S., Shin, H. J., Ding, E. L. & van Dam, R. M. Adiponectin levels and risk of type 2 diabetes: a 
systematic review and meta-analysis. JAMA. 302, 179-188 (2009). 
2159 citations identified  
from literature research 
         from PubMed 
 
30 potentially relevant  
     articles for further full text  
     review 
30 articles comprising 32      
eligible cohorts included in the 
meta-analysis 
1 article – current study 
2129 citations excluded based on     
            screening of titles or abstracts  
              using general data  
       
       1327   Not relevant (animal  
                  studies, or did not study  
                  either adiponectin or  
                  diabetes) 
       134     Other types of diabetes 
       668     Other publication or study 
                  Types (review, cross-  
                  Sectional, case-control,  
                  Commentary, meeting 
                  Abstract editorial etc.) 
11 articles excluded due to:  
    1   case-control study  
    8   studies where adiponectin or       
         type 2 diabetes is not the main  
         topic 
    2   duplicate publications 
13 articles added from the last meta-
analysisa 
2 articles excluded due to duplicate 
publications  
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